Unihealth pushed its 1,000-bed target out by two years and then said it always planned it that way.
Management delayed the landmark expansion from FY26 to CY28, but on the June call claimed the new timeline matched its 2023 guidance. Ugandan receivables have ballooned to 320 days.
What's new
- FY26 revenue rose 34.6% to ₹137 cr, with PAT up 83% to ₹25.8 cr.
- Bed capacity expanded from 200 to 400; Nashik 200-bed commissioning targeted early July FY27.
- Uganda receivable days hit 320; management says government is restructuring to 180-200 days.
Themes from the call
Timeline
The 1,000-bed expansion target has been pushed from FY26 to CY28, but management is claiming consistency with prior guidance.
Working Capital
Ugandan receivables have deteriorated sharply to 320 days, with management now treating 180-200 days as a recovery.
Expansion
Domestic expansion is on track, with Nashik and Navi Mumbai on schedule and a Tanzania acquisition pending.
Guidance watch
- FY27 revenue target of ₹250-300 cr at 60% occupancy and ₹27,500 ARPOB.
- CY28 target of 1,000 commissioned beds with ₹1-1.1 cr revenue per bed by FY29.
- Navi Mumbai operational break-even targeted for Q2 FY27.
Risk flags
- Management's attempt to rewrite the 1,000-bed timeline without acknowledging a multi-year delay.
- Ugandan receivables at 320 days are a material working capital risk, even with government restructuring.
- The Tanzania syringe manufacturing project mentioned in 2023-24 calls has disappeared from discussion.
Key quotes
-
"Our mission is to increase our bed capacity to roughly around 1,000 beds... targeted by the end of fiscal year 2025-26."
— Unihealth management, Nov 2023 call -
"The target remains what we have shared since 2023: by the end of calendar year 2028, we are targeting 1,000 commissioned beds."
— Dr. Akshay Parmar, Jun 2026 call -
"In Uganda, that goes up to almost four, four-and-a-half months."
— Unihealth management, May 2024 call -
"The Ugandan government has been structuring payments to... bring receivable days down from 320 to about 180-200."
— Dr. Akshay Parmar, Jun 2026 call
The brief
Unihealth Hospitals is having a good quarter on the numbers. Revenue grew 35% to ₹137 cr, PAT jumped 83%, and EBITDA margin expanded 400 basis points to 42.9%. The 200-bed Nashik facility is on track for a July launch, and Navi Mumbai is on pace for a Q2 break-even. But the earnings call exposed serious credibility issues on two fronts.
The most glaring is the 1,000-bed timeline. In November 2023, management guided to hitting 1,000 beds by the end of FY26. This quarter, Dr. Akshay Parmar said the target is now CY28, but added it was "what we have shared since 2023." That is a rewriting of the record. The three-year delay is material; the claim it was always the plan is not.
The second issue is Ugandan receivables. In May 2024, management said the working capital cycle was four to four-and-a-half months. This quarter, it revealed receivables were actually 320 days and framed the government's plan to get them to 180-200 days as progress. That is a deterioration, not an improvement. The Tanzania syringe manufacturing plant, promoted in 2023 and 2024 calls, has also vanished from discussion without explanation.
The growth story itself is intact. The company is on a path to 500-600 beds in FY27 and maintains its CY28 vision. But management's attempt to pretend the timeline and receivables situation were always as stated makes the forward guidance harder to trust. The numbers are good. The explanations are not.
Unihealth's operational execution is ahead of its credibility.